Promising brain tumor treatment study halted before it began
NCT ID NCT06466798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a new way to treat brain tumors that came back after standard therapy. The plan was to deliver immunotherapy (nivolumab) plus chemotherapy directly into the fluid spaces of the brain in children and adults. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted radiation zaps childhood brain tumors in early trial
- Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
- Parental distress may undermine treatment in children with recurrent brain tumors
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- New hope for kids with tough brain tumors: gene therapy meets immunotherapy and radiation
- Targeted drug shows promise for kids with tough cancers